Patents by Inventor Chitra Venugopal

Chitra Venugopal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STEAROYL-COA DESATURASE 1 (SCD1) INHIBITORS FOR THE TREATMENT OF HIGH-RISK MEDULLOBLASTOMA
    Publication number: 20260166032
    Abstract: This disclosure relates to stearoyl-CoA Desaturase 1 (SCD1) inhibitors for treating medulloblastoma such as high risk medulloblastoma. For example, the high risk medulloblastoma comprises a G3 medulloblastoma, a G4 medulloblastoma, G3 medulloblastoma that is MYC amplified (MYC-driven G3-MB), or a G4 medulloblastoma that is MYC amplified (MYC-driven G4-MB).
    Type: Application
    Filed: October 10, 2025
    Publication date: June 18, 2026
    Inventors: Sheila Singh, Chitra Venugopal, Stefan Custers
  • CD133-binding agents and uses thereof
    Patent number: 12595312
    Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: April 7, 2026
    Assignees: The Governing Council of the University of Toronto, McMaster University
    Inventors: Jason Moffat, Jarrett Adams, Guohua Pan, Sachdev Sidhu, Rashida Williams, Xiaoyu Zhang, Sheila K. Singh, Parvez Vora, Chitra Venugopal
  • METHODS FOR TREATING MYC-AMPLIFIED CANCER
    Publication number: 20250152559
    Abstract: The present disclosure relates to the treatment of a myc-amplified cancer using a DHODH inhibitor. Also disclosed herein are combination therapies, compositions and kits for the treatment of a myc-amplified cancer comprising a DHODH inhibitor.
    Type: Application
    Filed: November 12, 2024
    Publication date: May 15, 2025
    Inventors: Jason Moffat, Jose Rafael Montenegro Burke, Sheila K. Singh, William D. Gwynne, Chitra Venugopal
  • CD133-BINDING AGENTS AND USES THEREOF
    Publication number: 20220073640
    Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.
    Type: Application
    Filed: October 26, 2021
    Publication date: March 10, 2022
    Inventors: Jason Moffat, Jarrett Adams, Guohua Pan, Sachdev Sidhu, Rashida Williams, Xiaoyu Zhang, Sheila K. Singh, Parvez Vora, Chitra Venugopal
  • CD133-binding agents and uses thereof
    Patent number: 11220551
    Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: January 11, 2022
    Assignees: The Governing Council of the University of Toronto, McMaster University
    Inventors: Jason Moffat, Jarrett Adams, Guohua Pan, Sachdev Sidhu, Rashida Williams, Xiaoyu Zhang, Sheila K. Singh, Parvez Vora, Chitra Venugopal
  • PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF
    Publication number: 20200277268
    Abstract: The present application relates to sulfonamide containing compounds of Formulae (I) and (II) and compositions containing said compounds effective in the treatment of cell proliferative disorders, in particular cancer, and various methods of use thereof.
    Type: Application
    Filed: September 21, 2018
    Publication date: September 3, 2020
    Applicant: Dalriada Therapeutics Inc.
    Inventors: Patrick Thomas Gunning, Ji Sung Park, Siawash Ahmar, David Alexander Rosa, Dziyana Kraskouskaya, David Bakhshinyan, Sheila Singh, Chitra Venugopal, Angelika Berger-Becvar, Mulu Geletu-Heye, Mariya Bogatchenko, Elvin De Araujo, Diana Sina
  • CD133-BINDING AGENTS AND USES THEREOF
    Publication number: 20190330362
    Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.
    Type: Application
    Filed: October 19, 2017
    Publication date: October 31, 2019
    Inventors: Jason Moffat, Jarrett Adams, Guohua Pan, Sachdev Sidhu, Rashida Williams, Xiaoyu Zhang, Sheila K. Singh, Parvez Vora, Chitra Venugopal